Base de dados : MEDLINE
Pesquisa : C04.588.614 [Categoria DeCS]
Referências encontradas : 1578 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 158 ir para página                         

  1 / 1578 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28746860
[Au] Autor:Rogawski DS; Vitanza NA; Gauthier AC; Ramaswamy V; Koschmann C
[Ad] Endereço:Department of Pediatrics, University of Michigan School of Medicine, Ann Arbor, Mich.
[Ti] Título:Integrating RNA sequencing into neuro-oncology practice.
[So] Source:Transl Res;189:93-104, 2017 Nov.
[Is] ISSN:1878-1810
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Malignant tumors of the central nervous system (CNS) cause substantial morbidity and mortality, yet efforts to optimize chemo- and radiotherapy have largely failed to improve dismal prognoses. Over the past decade, RNA sequencing (RNA-seq) has emerged as a powerful tool to comprehensively characterize the transcriptome of CNS tumor cells in one high-throughput step, leading to improved understanding of CNS tumor biology and suggesting new routes for targeted therapies. RNA-seq has been instrumental in improving the diagnostic classification of brain tumors, characterizing oncogenic fusion genes, and shedding light on intratumor heterogeneity. Currently, RNA-seq is beginning to be incorporated into regular neuro-oncology practice in the form of precision neuro-oncology programs, which use information from tumor sequencing to guide implementation of personalized targeted therapies. These programs show great promise in improving patient outcomes for tumors where single agent trials have been ineffective. As RNA-seq is a relatively new technique, many further applications yielding new advances in CNS tumor research and management are expected in the coming years.
[Mh] Termos MeSH primário: Oncologia
Neoplasias do Sistema Nervoso/genética
Análise de Sequência de RNA/métodos
[Mh] Termos MeSH secundário: Regulação Neoplásica da Expressão Gênica
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  2 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29068998
[Au] Autor:Fetcko K; Lukas RV; Watson GA; Zhang L; Dey M
[Ad] Endereço:aDepartment of Neurosurgery, Indiana University, Indianapolis, IN bDepartment of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philidelphia, PA cDepartment of Neurology, Northwestern University, Chicago, IL dDepartment of Radiation Oncology, Simon Cancer Center, Indiana University, Indianapolis, IN.
[Ti] Título:Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas.
[So] Source:Medicine (Baltimore);96(43):e8293, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Utilization of stereotactic radiosurgery (SRS) for treatment of high-grade gliomas (HGGs) has been slowly increasing with variable reported success rates. OBJECTIVE: Systematic review of the available data to evaluate the efficacy of SRS as a treatment for HGG with regards to median overall survival (OS) and progression-free survival (PFS), in addition to ascertaining the rate of radiation necrosis and other SRS-related major neurological complications. METHODS: Literature searches were performed for publications from 1992 to 2016. The pooled estimates of median PFS and median OS were calculated as a weighted estimate of population medians. Meta-analyses of published rates of radiation necrosis and other major neurological complications were also performed. RESULTS: Twenty-nine studies reported the use of SRS for recurrent HGG, and 16 studies reported the use of SRS for newly diagnosed HGG. For recurrent HGG, the pooled estimates of median PFS and median OS were 5.42 months (3-16 months) and 20.19 months (9-65 months), respectively; the pooled radiation necrosis rate was 5.9% (0-44%); and the pooled estimates of major neurological complications rate was 3.3% (0-23%). For newly diagnosed HGG, the pooled estimates of median PFS and median OS were 7.89 months (5.5-11 months) and 16.87 months (9.5-33 months) respectively; the pooled radiation necrosis rate was 6.5% (0-33%); and the pooled estimates of other major neurological complications rate was 1.5% (0-25%). CONCLUSION: Our results suggest that SRS holds promise as a relatively safe treatment option for HGG. In terms of efficacy at this time, there are inadequate data to support routine utilization of SRS as the standard of care for newly diagnosed or recurrent HGG. Further studies should be pursued to define more clearly the therapeutic role of SRS.
[Mh] Termos MeSH primário: Glioma
Recidiva Local de Neoplasia/cirurgia
Neoplasias do Sistema Nervoso
Complicações Pós-Operatórias
Radiocirurgia
[Mh] Termos MeSH secundário: Intervalo Livre de Doença
Glioma/patologia
Glioma/cirurgia
Seres Humanos
Gradação de Tumores
Neoplasias do Sistema Nervoso/patologia
Neoplasias do Sistema Nervoso/cirurgia
Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/etiologia
Radiocirurgia/efeitos adversos
Radiocirurgia/métodos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171126
[Lr] Data última revisão:
171126
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171026
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008293


  3 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28801062
[Au] Autor:Tsai CY; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
[Ad] Endereço:Division of Thoracic Surgery, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
[Ti] Título:Perineural invasion through the sheath in posttherapy esophagectomy specimens predicts poor survival in patients with esophageal squamous cell carcinoma.
[So] Source:Eur J Surg Oncol;43(10):1970-1976, 2017 Oct.
[Is] ISSN:1532-2157
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The prognostic impact of perineural invasion (PNI) in patients with esophageal cancer who receive neoadjuvant chemoradiotherapy (nCRT) remains unclear. METHODS: A thorough pathological review of PNI was performed on post-nCRT esophagectomy specimens obtained from non-ypT0 patients with esophageal squamous cell carcinoma (ESCC). When PNI was identified, it was classified according to the presence or absence of penetration through the nerve sheath (i.e., PNI surrounding the nerve sheath [PNI-SS] versus PNI penetrating through the nerve sheath [PNI-TS]). The impact of PNI on overall survival (OS) was assessed in combination with clinical and pathological risk factors. RESULTS: A total of 177 eligible patients were identified between 1998 and 2008. PNI was identified in 43.5% (77/177) of participants. Of them, 33 and 44 had PNI-SS and PNI-TS, respectively. The 5-year OS rate of patients with PNI-TS was significantly lower (6.7%) than that observed in those without PNI (30.6%, P < 0.001). However, the 5-year OS observed in the latter group did not differ significantly from that of patients with PNI-SS (26%, P = 0.68). Multivariate analysis identified PNI-TS (hazard ratio [HR] = 1.965, P = 0.02), LVI (HR = 1.514, P = 0.048), and ypN2 stage (HR = 2.39, P = 0.007) as independent adverse prognostic factors for OS. CONCLUSIONS: The presence of PNI-TS after nCRT is associated with poor survival. A thorough assessment of distinct PNI patterns (i.e., PNI-TS versus PNI-SS) should be part of the routine post-nCRT histopathological work-up of ESCC patients.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/patologia
Neoplasias Esofágicas/patologia
Esofagectomia/métodos
Neoplasias do Sistema Nervoso/patologia
[Mh] Termos MeSH secundário: Carcinoma de Células Escamosas/mortalidade
Carcinoma de Células Escamosas/terapia
Quimiorradioterapia
Intervalo Livre de Doença
Neoplasias Esofágicas/mortalidade
Neoplasias Esofágicas/terapia
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Terapia Neoadjuvante
Invasividade Neoplásica
Estadiamento de Neoplasias
Prognóstico
Estudos Retrospectivos
Fatores de Risco
Taxa de Sobrevida/tendências
Taiwan/epidemiologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170813
[St] Status:MEDLINE


  4 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28362995
[Au] Autor:Zhao C; Ma ZG; Mou SL; Yang YX; Zhang YH; Yao WC
[Ad] Endereço:Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
[Ti] Título:Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells.
[So] Source:Genet Mol Res;16(1), 2017 Mar 30.
[Is] ISSN:1676-5680
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:MiR-200b, a member of the microRNA-200 family, has been identified to be capable of suppressing glioma cell growth through targeting CREB1 or CD133. However, whether miR-200b affects the biological behavior (proliferation, invasion, and migration) of glioma cells is poorly understood. The aim of this study was to evaluate the effect of miR-200b on the biological behavior of glioma cells in vitro. MiRNA-200b mimics, miRNA-200b inhibitor, and mimic control were transfected into conventionally cultured glioma U251 cells, followed by measuring the expression of miR-200b and CD133 in transfected cells by RT-PCR; effect of miR-200b on CD133 mRNA 3'-UTR luciferase activity by luciferase reporter assay; proliferation activity of transfected U251 cells by MTT method; and changes in U251 cell invasion and migration by Transwell method after transfection. Compared to that in the miRNA-200b inhibitor, mimic control, and blank control groups, miRNA-200b expression was significantly increased and CD133 mRNA expression was significantly decreased in the mimic miRNA-200b group in a time-dependent manner (P < 0.05). Meanwhile, dual luciferase reporter assay showed that miR-200b could inhibit CD133 activity through binding to the 3'-UTR of CD133 mRNA (P < 0.05). Furthermore, the proliferation activity and invasion and migration abilities of U251 cells transfected with miRNA-200b mimic were significantly decreased (P < 0.05). In conclusion, overexpression of miR-200b inhibited the proliferation, invasion, and migration of glioma cells possibly through targeting CD133.
[Mh] Termos MeSH primário: Antígeno AC133/genética
Glioma/genética
MicroRNAs/genética
[Mh] Termos MeSH secundário: Regiões 3' não Traduzidas
Antígeno AC133/metabolismo
Apoptose/genética
Ciclo Celular/genética
Linhagem Celular Tumoral
Movimento Celular/genética
Proliferação Celular/genética
Regulação Neoplásica da Expressão Gênica
Glioma/metabolismo
Glioma/patologia
Seres Humanos
MicroRNAs/biossíntese
MicroRNAs/metabolismo
Neoplasias do Sistema Nervoso/genética
Neoplasias do Sistema Nervoso/metabolismo
Neoplasias do Sistema Nervoso/patologia
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Transfecção
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3' Untranslated Regions); 0 (AC133 Antigen); 0 (MIRN200 microRNA, human); 0 (MicroRNAs); 0 (PROM1 protein, human); 0 (RNA, Messenger)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170503
[Lr] Data última revisão:
170503
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170401
[St] Status:MEDLINE
[do] DOI:10.4238/gmr16019281


  5 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28125533
[Au] Autor:Domeshek LF; Krauss EM; Snyder-Warwick AK; Laurido-Soto O; Hasak JM; Skolnick GB; Novak CB; Moore AM; Mackinnon SE
[Ad] Endereço:St. Louis, Mo.; and Toronto, Ontario, CanadaFrom the Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University in St. Louis School of Medicine; and the Hand and Upper Extremity Program, Division of Plastic and Reconstructive Surgery, University of Toronto.
[Ti] Título:Surgical Treatment of Neuromas Improves Patient-Reported Pain, Depression, and Quality of Life.
[So] Source:Plast Reconstr Surg;139(2):407-418, 2017 Feb.
[Is] ISSN:1529-4242
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Surgical management of neuromas is difficult, with no consensus on the most effective surgical procedure to improve pain and quality of life. This study evaluated the surgical treatment of neuromas by neurectomy, crush, and proximal transposition on improvement in pain, depression, and quality of life. METHODS: Patients who underwent neuroma excision and proximal transposition were evaluated. Preoperative and postoperative visual analogue scale scores for pain (worst and average), depression, and quality of life were assessed using linear regression, and means were compared using paired t tests. The Disabilities of the Arm, Shoulder, and Hand questionnaire score was calculated preoperatively and postoperatively for upper extremity neuroma patients. Patients with long-term follow-up were analyzed using repeated measures analysis of variance comparing preoperative, postoperative, and long-term visual analogue scale scores. RESULTS: Seventy patients (37 with upper extremity neuromas and 33 with lower extremity neuromas) met inclusion criteria. Statistically significant improvements in visual analogue scale scores were demonstrated for all four patient-rated qualities (p < 0.01) independent of duration of initial clinical follow-up. The change in preoperative to postoperative visual analogue scale scores was related inversely to the severity of preoperative scores for pain and depression. Neuroma excision and proximal transposition were equally effective in treating lower and upper extremity neuromas. Upper extremity neuroma patients had a statistically significant improvement in Disabilities of the Arm, Shoulder, and Hand questionnaire scores after surgical treatment (p < 0.02). CONCLUSIONS: Surgical neurectomy, crush, and proximal nerve transposition significantly improved self-reported pain, depression, and quality-of-life scores. Surgical intervention is a viable treatment of neuroma pain and should be considered in patients with symptomatic neuromas refractory to nonoperative management. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
[Mh] Termos MeSH primário: Depressão/etiologia
Neoplasias do Sistema Nervoso/cirurgia
Neuroma/complicações
Neuroma/cirurgia
Dor/etiologia
Medidas de Resultados Relatados pelo Paciente
Qualidade de Vida
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Depressão/prevenção & controle
Feminino
Seres Humanos
Masculino
Meia-Idade
Procedimentos Neurocirúrgicos
Dor/prevenção & controle
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170127
[St] Status:MEDLINE
[do] DOI:10.1097/PRS.0000000000003018


  6 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28006863
[Au] Autor:Frank C; Sundquist J; Yu H; Hemminki A; Hemminki K
[Ad] Endereço:Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, Heidelberg, D-69120, Germany.
[Ti] Título:Concordant and discordant familial cancer: Familial risks, proportions and population impact.
[So] Source:Int J Cancer;140(7):1510-1516, 2017 Apr 01.
[Is] ISSN:1097-0215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Relatives of cancer patients are at an increased risk of the same (concordant) cancer but whether they are at a risk for different (discordant) cancers is largely unknown - beyond well characterized hereditary cancer syndromes - but would be of major scientific and clinical interest. We therefore decided to resolve the issue by analyzing familial risks when family members were diagnosed with any discordant cancers. We compared the population impact of concordant to discordant familial cancer. The Swedish Family-Cancer Database (FCD) was used to calculate familial relative risks (RRs) for family members of cancer patients, for the 27 most common cancers. Population attributable fractions (PAFs) were estimated for concordant and discordant family histories. Discordant cancers in the family were detected as significant risk factors for the majority of cancers, although the corresponding RRs were modest compared to RRs for concordant cancers. Risks increased with the number of affected family members with the highest RRs for pancreatic (2.31), lung (1.69), kidney (1.98), nervous system (1.79) and thyroid cancers (3.28), when 5 or more family members were diagnosed with discordant cancers. For most cancers, the PAF for discordant family history exceeded that for concordant family history. Our findings suggest that there is an unspecific genetic predisposition to cancer with clinical consequences. We consider it unlikely that shared environmental risk factors could essentially contribute to the risks for diverse discordant cancers, which are likely driven by genetic predisposition. The identification of genes that moderately increase the risk for many cancers will be a challenge.
[Mh] Termos MeSH primário: Neoplasias/epidemiologia
Neoplasias/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Bases de Dados Factuais
Saúde da Família
Feminino
Predisposição Genética para Doença
Seres Humanos
Neoplasias Renais/genética
Neoplasias Pulmonares/genética
Masculino
Meia-Idade
Neoplasias/diagnóstico
Neoplasias do Sistema Nervoso/genética
Neoplasias Pancreáticas/genética
Sistema de Registros
Fatores de Risco
Suécia
Neoplasias da Glândula Tireoide/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170502
[Lr] Data última revisão:
170502
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161223
[St] Status:MEDLINE
[do] DOI:10.1002/ijc.30583


  7 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28001089
[Au] Autor:Karmakar S; Reilly KM
[Ad] Endereço:Rare Tumors Initiative, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr, Bethesda, MD 20814, USA.
[Ti] Título:The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.
[So] Source:CNS Oncol;6(1):45-60, 2017 01.
[Is] ISSN:2045-0915
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:With the recent development of new anticancer therapies targeting the immune system, it is important to understand which immune cell types and cytokines play critical roles in suppressing or promoting tumorigenesis. The role of mast cells in promoting neurofibroma growth in neurofibromatosis type 1 (NF1) patients was hypothesized decades ago. More recent experiments in mouse models have demonstrated the causal role of mast cells in neurofibroma development and of microglia in optic pathway glioma development. We review here what is known about the role of NF1 mutation in immune cell function and the role of immune cells in promoting tumorigenesis in NF1. We also review the therapies targeting immune cell pathways and their promise in NF1 tumors.
[Mh] Termos MeSH primário: Sistema Imunitário/fisiologia
Mutação/genética
Neoplasias do Sistema Nervoso/imunologia
Neurofibromatose 1/imunologia
Neurofibromina 1/genética
[Mh] Termos MeSH secundário: Animais
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Sistema Imunitário/patologia
Neoplasias do Sistema Nervoso/genética
Neurofibromatose 1/genética
Transdução de Sinais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., INTRAMURAL; REVIEW
[Nm] Nome de substância:
0 (Neurofibromin 1)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.2217/cns-2016-0024


  8 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27785931
[Au] Autor:Kumar A; Dhull DK; Gupta V; Channana P; Singh A; Bhardwaj M; Ruhal P; Mittal R
[Ad] Endereço:a Neuropharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies (UGC-CAS) , Panjab University , Chandigarh , India.
[Ti] Título:Role of Glutathione-S-transferases in neurological problems.
[So] Source:Expert Opin Ther Pat;27(3):299-309, 2017 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Role of Glutathione-S-transferases (GSTs) has been well explored in the cellular detoxification process, regulation of redox homeostasis and S-glutothionylation of target proteins like JNK, ASK1 etc. However, altered levels or functions of this enzyme or their subtypes have emerged in the development of several pathologies diseases such as Alzheimer's disease, Parkinson's disease, cancer and related conditions. Oxidative stress is one of the possible pathological events that contributes significantly to activation of degenerating cascades inside neuronal cells. The central nervous system is highly sensitive to oxidative stress because of low levels or capacities of antioxidant enzymes. The brain is highly metabolic in nature making it susceptible to oxidative stress. Areas covered: The present review provides a comprehensive overview of the multiple connections of GSTs within diverse neurological diseases including cancer. Furthermore, the authors have made significant efforts to discuss the regulation of different GST isoforms that have been associated with various pathological processes such as glioblastoma, Alzheimer's disease, Parkinson's disease, stroke and epilepsy. Expert opinion: Though GSTs have been one of the key areas of scientific research over the last few decades, much remains to be elucidated about their physiological functions as well as pathological involvement of GSTs and their polymorphic variants.
[Mh] Termos MeSH primário: Glutationa Transferase/metabolismo
Doenças do Sistema Nervoso/fisiopatologia
Estresse Oxidativo/fisiologia
[Mh] Termos MeSH secundário: Animais
Antioxidantes/metabolismo
Encéfalo/enzimologia
Encéfalo/patologia
Seres Humanos
Isoenzimas
Doenças do Sistema Nervoso/enzimologia
Neoplasias do Sistema Nervoso/enzimologia
Neoplasias do Sistema Nervoso/patologia
Patentes como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antioxidants); 0 (Isoenzymes); EC 2.5.1.18 (Glutathione Transferase)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170310
[Lr] Data última revisão:
170310
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161028
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2017.1254192


  9 / 1578 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27511313
[Au] Autor:Sisó S; Marco-Salazar P; Moore PF; Sturges BK; Vernau W; Wisner ER; Bollen AW; Dickinson PJ; Higgins RJ
[Ad] Endereço:1 Departments of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.
[Ti] Título:Canine Nervous System Lymphoma Subtypes Display Characteristic Neuroanatomical Patterns.
[So] Source:Vet Pathol;54(1):53-60, 2017 Jan.
[Is] ISSN:1544-2217
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary and secondary nervous system involvement occurs in 4% and 5%-12%, respectively, of all canine non-Hodgkin lymphomas. The recent new classification of canine malignant lymphomas, based on the human World Health Organization classification, has been endorsed with international acceptance. This histological and immunocytochemical classification provides a unique opportunity to study the histologic anatomic distribution patterns in the central and peripheral nervous system of these defined lymphoma subtypes. In this study, we studied a cohort of 37 dogs with lymphoma, which at necropsy had either primary (n = 1, 2.7%) or secondary (n = 36; 97.3%) neural involvement. These T- (n = 16; 43.2%) or B-cell (n = 21; 56.8%) lymphomas were further classified into 12 lymphoma subtypes, with predominant subtypes including peripheral T-cell lymphoma (PTCL) or diffuse large B-cell lymphoma (DLBCL), respectively. This systematic study identified 6 different anatomically based histologically defined patterns of lymphoma infiltration in the nervous system of dogs. Different and distinct combinations of anatomical patterns correlated with specific lymphoma subtypes. Lymphoma infiltration within the meningeal, perivascular, and periventricular compartments were characteristic of DLBCL, whereas peripheral nerve involvement was a frequent feature of PTCL. Similarly cell counts above 64 cells/µL in cerebrospinal samples correlated best with marked meningeal and periventricular lymphoma infiltration histologically. Prospective studies are needed in order to confirm the hypothesis that these combinations of histological neuroanatomic patterns reflect targeting of receptors specific for the lymphoma subtypes at these various sites.
[Mh] Termos MeSH primário: Doenças do Cão/patologia
Linfoma/veterinária
Neoplasias do Sistema Nervoso/veterinária
[Mh] Termos MeSH secundário: Animais
Cães
Feminino
Linfoma/patologia
Linfoma de Células B/patologia
Linfoma de Células B/veterinária
Linfoma de Células T/patologia
Linfoma de Células T/veterinária
Masculino
Neoplasias do Sistema Nervoso/patologia
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160812
[St] Status:MEDLINE
[do] DOI:10.1177/0300985816658101


  10 / 1578 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27235704
[Au] Autor:Lam L; Woollard GA; Teague L; Davidson JS
[Ad] Endereço:1 Department of Chemical Pathology, Labplus, Auckland City Hospital, Auckland, New Zealand.
[Ti] Título:Clinical validation of urine 3-methoxytyramine as a biomarker of neuroblastoma and comparison with other catecholamine-related biomarkers.
[So] Source:Ann Clin Biochem;54(2):264-272, 2017 Mar.
[Is] ISSN:1758-1001
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background Urinary dopamine, homovanillic acid and 4-hydroxy-3-methoxymandelic acid are established tests for diagnosis and monitoring of neuroblastic disease. We compared the diagnostic performance of total urinary 3-methoxytyramine, the O-methylated product of dopamine, to these three established tumour markers. Methods Urinary 3-methoxytyramine, dopamine, homovanillic acid and 4-hydroxy-3-methoxymandelic acid were measured by high-performance liquid chromatography with electrochemical detection on consecutive urine samples from histologically proven neuroblastic patients and controls. Patients with neuroblastic disease were further classified as untreated, advancing, residual or absent disease based on clinical and radiological criteria. Receiver operating characteristic curve analysis was used to compare the diagnostic performance of the four tumour markers. Results Urinary 3-methoxytyramine was well correlated with established tumour markers and its concentration correlated with disease activity. It was the most commonly elevated tumour marker in neuroblastic disease and showed similar sensitivity to dopamine and homovanillic acid. The diagnostic utility of urinary 3-methoxytyramine as measured by area under the receiver operating characteristic curve was similar to dopamine and homovanillic acid. Conclusion Our results support the use of urinary 3-methoxytyramine as a tumour marker in the diagnosis and the monitoring of neuroblastoma disease.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/urina
Dopamina/análogos & derivados
Neoplasias do Sistema Nervoso/diagnóstico
Neoplasias do Sistema Nervoso/urina
Neuroblastoma/diagnóstico
Neuroblastoma/urina
[Mh] Termos MeSH secundário: Estudos de Casos e Controles
Criança
Pré-Escolar
Cromatografia Líquida de Alta Pressão
Dopamina/urina
Feminino
Ácido Homovanílico/urina
Seres Humanos
Lactente
Recém-Nascido
Masculino
Metanefrina/urina
Estadiamento de Neoplasias
Neoplasia Residual
Neoplasias do Sistema Nervoso/patologia
Neuroblastoma/patologia
Curva ROC
Sistema Nervoso Simpático/metabolismo
Sistema Nervoso Simpático/patologia
Ácido Vanilmandélico/urina
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 5001-33-2 (Metanephrine); 55-10-7 (Vanilmandelic Acid); JCH2767EDP (3-methoxytyramine); VTD58H1Z2X (Dopamine); X77S6GMS36 (Homovanillic Acid)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170714
[Lr] Data última revisão:
170714
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160529
[St] Status:MEDLINE
[do] DOI:10.1177/0004563216654723



página 1 de 158 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde